<p>Humacyte, Inc.（纳斯达克代码：HUMA - 获取免费报告）内部人士 Shamik J. Parikh 于 4 月 10 日星期四购买了 7,500 股该股票。每股平均购买价格为 1.55 美元，总交易额为 11,625.00 美元。购买完成后，该内部人士现在直接拥有 7,500 股公司股票，价值约为 11,625 美元。这笔交易代表了他们对该股票的持有量增加了∞。该交易已在向美国证券交易委员会（SEC）的备案中披露，具体内容可通过此链接查看。</p>
<h2>Humacyte 股价上涨 2.9%</h2>
<p>在周一的交易中，HUMA 股票上涨 0.05 美元，达到 1.58 美元。该股票成交量为 1,142,258 股，而其平均成交量为 3,554,488 股。该股票的市值为 2.2813 亿美元，市盈率为-1.18，贝塔值为 1.62。Humacyte, Inc.的股价在过去一年内最低为 1.15 美元，最高为 9.97 美元。该公司的 50 日简单移动平均线为 2.87 美元，200 日简单移动平均线为 4.16 美元。</p>
<p>Humacyte（纳斯达克代码：HUMA - 获取免费报告）最近一次公布财报是在 3 月 28 日星期五。该公司报告本季度每股收益（EPS）为-0.16 美元，超出市场共识预期的-0.23 美元，超出幅度为 0.07 美元。该季度的营业收入为 723 万美元，而分析师预期为 64 万美元。整体来看，分析师预测 Humacyte, Inc.在当前财政年度的每股收益为-1.27 美元。</p>
<h2>华尔街分析师观点</h2>
<p>HUMA 已成为多份研究报告的主题。D. Boral Capital 在 3 月 26 日星期三的研究报告中重申了对 Humacyte 的 “买入” 评级，并设定了 25.00 美元的目标价。HC Wainwright 在 3 月 12 日星期三的研究报告中重申了对 Humacyte 的 “买入” 评级，并发布了 15.00 美元的目标价。最后，Benchmark 在 2 月 27 日星期四的研究报告中重申了对 Humacyte 的 “买入” 评级。一位股票研究分析师对该股票给予了持有评级，六位分析师给予了买入评级，一位分析师给予了强烈买入评级。根据 MarketBeat.com 的数据，该股票目前的共识评级为 “买入”，共识目标价为 13.71 美元。</p>
<p><strong>查看我们最新的 Humacyte 股票报告</strong></p>
<h2>Humacyte 的机构交易</h2>
<p>几家大型投资者最近对 HUMA 的持仓进行了调整。Woodline Partners LP 在第四季度将其在 Humacyte 的持股增加了 235.7%。Woodline Partners LP 现在拥有 2,848,802 股公司股票，价值 1,438.6 万美元，此前在上个季度又购买了 2,000,268 股。State Street Corp 在第三季度将其在 Humacyte 的持仓增加了 66.1%。State Street Corp 现在拥有 4,764,155 股公司股票，价值 2,591.7 万美元，此前在上个季度又收购了 1,895,529 股。CenterBook Partners LP 在第四季度购买了 Humacyte 的新头寸，价值约 646.3 万美元。Brevan Howard Capital Management LP 在第四季度将其在 Humacyte 的持仓增加了 2,795.1%。Brevan Howard Capital Management LP 现在拥有 876,340 股公司股票，价值 442.6 万美元，此前在上个季度又购买了 846,070 股。最后，Vanguard Group Inc.在第四季度将其在 Humacyte 的持股增加了 10.8%。Vanguard Group Inc.现在拥有 5,602,684 股公司股票，价值 2,829.4 万美元，此前在上个季度又购买了 543,995 股。机构投资者持有公司 44.71% 的股票。</p>
<h2>关于 Humacyte</h2>
<p>（获取免费报告）</p>
<p>Humacyte, Inc.从事开发和制造现成的、可植入的生物工程人类组织，以治疗多种解剖部位的疾病和状况。该公司利用其专有的科学技术平台，工程化和制造人类无细胞血管（HAV），以便植入患者体内而不引发外来物体反应或导致免疫排斥。</p>
<h2>了解更多</h2>
<ul>
<li>我们更看好的五只股票，胜过 Humacyte</li>
<li>3 只最佳金融科技股票，助力投资组合提升</li>
<li>第一季度内部人士购买的三只大型股：买入、卖出或持有</li>
<li>医疗保健股票解析：为什么你可能想要投资</li>
<li>3 只热销新 IPO，逆势而上，抵御 2025 年市场下滑</li>
<li>如何最有效地使用 MarketBeat 财报筛选器</li>
<li>3 只高收益分红股票，当前交易价格折扣</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9SFVNQQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9SFVNQQ"/></p>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。如对该故事有任何问题或意见，请发送电子邮件至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 Humacyte 吗？</h2>
<p>在你考虑 Humacyte 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，建议现在购买，以便在更广泛的市场注意到之前...而 Humacyte 并不在名单上。</p>
<p>虽然 Humacyte 目前在分析师中获得了买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>查看这五只股票</p>

HUMA

<p>Shamik J. Parikh，Humacyte, Inc.（NASDAQ:HUMA）的内部人士，于 4 月 10 日以每股 1.55 美元的价格购买了 7,500 股，总计 11,625 美元。这次收购增加了他在公司的持股比例。交易后，HUMA 的股价上涨了 2.9%，达到 1.58 美元。Humacyte 报告的季度每股收益为（0.16 美元），超出预期，收入为 723 万美元。分析师维持一致的 “买入” 评级，目标价为 13.71 美元。机构投资者持有 Humacyte 44.71% 的股份，反映出对该公司的显著兴趣</p>

<p>Humacyte, Inc. (NASDAQ:HUMA - Get Free Report) insider Shamik J. Parikh purchased 7,500 shares of the stock in a transaction that occurred on Thursday, April 10th. The shares were purchased at an average price of $1.55 per share, for a total transaction of $11,625.00. Following the completion of the purchase, the insider now directly owns 7,500 shares of the company's stock, valued at approximately $11,625. This trade represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link.</p>
<div class="lb-trans"><p>Humacyte, Inc.（纳斯达克代码：HUMA - 获取免费报告）内部人士 Shamik J. Parikh 于 4 月 10 日星期四购买了 7,500 股该股票。每股平均购买价格为 1.55 美元，总交易额为 11,625.00 美元。购买完成后，该内部人士现在直接拥有 7,500 股公司股票，价值约为 11,625 美元。这笔交易代表了他们对该股票的持有量增加了∞。该交易已在向美国证券交易委员会（SEC）的备案中披露，具体内容可通过此链接查看。</p>
</div><h2>Humacyte Trading Up 2.9 %</h2>
<div class="lb-trans"><h2>Humacyte 股价上涨 2.9%</h2>
</div><p>HUMA stock traded up $0.05 during trading on Monday, hitting $1.58. 1,142,258 shares of the stock traded hands, compared to its average volume of 3,554,488. The stock has a market cap of $228.13 million, a price-to-earnings ratio of -1.18 and a beta of 1.62. Humacyte, Inc. has a one year low of $1.15 and a one year high of $9.97. The company has a 50 day simple moving average of $2.87 and a 200 day simple moving average of $4.16.</p>
<div class="lb-trans"><p>在周一的交易中，HUMA 股票上涨 0.05 美元，达到 1.58 美元。该股票成交量为 1,142,258 股，而其平均成交量为 3,554,488 股。该股票的市值为 2.2813 亿美元，市盈率为-1.18，贝塔值为 1.62。Humacyte, Inc.的股价在过去一年内最低为 1.15 美元，最高为 9.97 美元。该公司的 50 日简单移动平均线为 2.87 美元，200 日简单移动平均线为 4.16 美元。</p>
</div><p>Humacyte (NASDAQ:HUMA - Get Free Report) last announced its earnings results on Friday, March 28th. The company reported ($0.16) EPS for the quarter, topping the consensus estimate of ($0.23) by $0.07. The business had revenue of $7.23 million during the quarter, compared to analyst estimates of $0.64 million. As a group, analysts predict that Humacyte, Inc. will post -1.27 earnings per share for the current fiscal year.</p>
<div class="lb-trans"><p>Humacyte（纳斯达克代码：HUMA - 获取免费报告）最近一次公布财报是在 3 月 28 日星期五。该公司报告本季度每股收益（EPS）为-0.16 美元，超出市场共识预期的-0.23 美元，超出幅度为 0.07 美元。该季度的营业收入为 723 万美元，而分析师预期为 64 万美元。整体来看，分析师预测 Humacyte, Inc.在当前财政年度的每股收益为-1.27 美元。</p>
</div><h2>Wall Street Analyst Weigh In</h2>
<div class="lb-trans"><h2>华尔街分析师观点</h2>
</div><p>HUMA has been the topic of a number of research reports. D. Boral Capital restated a &#34;buy&#34; rating and set a $25.00 price objective on shares of Humacyte in a research report on Wednesday, March 26th. HC Wainwright restated a &#34;buy&#34; rating and issued a $15.00 price objective on shares of Humacyte in a research note on Wednesday, March 12th. Finally, Benchmark reiterated a &#34;buy&#34; rating on shares of Humacyte in a research report on Thursday, February 27th. One equities research analyst has rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of &#34;Buy&#34; and a consensus price target of $13.71.</p>
<div class="lb-trans"><p>HUMA 已成为多份研究报告的主题。D. Boral Capital 在 3 月 26 日星期三的研究报告中重申了对 Humacyte 的 “买入” 评级，并设定了 25.00 美元的目标价。HC Wainwright 在 3 月 12 日星期三的研究报告中重申了对 Humacyte 的 “买入” 评级，并发布了 15.00 美元的目标价。最后，Benchmark 在 2 月 27 日星期四的研究报告中重申了对 Humacyte 的 “买入” 评级。一位股票研究分析师对该股票给予了持有评级，六位分析师给予了买入评级，一位分析师给予了强烈买入评级。根据 MarketBeat.com 的数据，该股票目前的共识评级为 “买入”，共识目标价为 13.71 美元。</p>
</div><p><strong>Check Out Our Latest Stock Report on Humacyte</strong></p>
<div class="lb-trans"><p><strong>查看我们最新的 Humacyte 股票报告</strong></p>
</div><h2>Institutional Trading of Humacyte</h2>
<div class="lb-trans"><h2>Humacyte 的机构交易</h2>
</div><p>Several large investors have recently made changes to their positions in HUMA. Woodline Partners LP raised its holdings in shares of Humacyte by 235.7% in the fourth quarter. Woodline Partners LP now owns 2,848,802 shares of the company's stock valued at $14,386,000 after buying an additional 2,000,268 shares during the last quarter. State Street Corp increased its position in Humacyte by 66.1% in the 3rd quarter. State Street Corp now owns 4,764,155 shares of the company's stock valued at $25,917,000 after acquiring an additional 1,895,529 shares in the last quarter. CenterBook Partners LP bought a new position in shares of Humacyte in the fourth quarter worth about $6,463,000. Brevan Howard Capital Management LP lifted its position in shares of Humacyte by 2,795.1% during the fourth quarter. Brevan Howard Capital Management LP now owns 876,340 shares of the company's stock worth $4,426,000 after purchasing an additional 846,070 shares in the last quarter. Finally, Vanguard Group Inc. grew its stake in shares of Humacyte by 10.8% during the fourth quarter. Vanguard Group Inc. now owns 5,602,684 shares of the company's stock valued at $28,294,000 after purchasing an additional 543,995 shares during the last quarter. Institutional investors own 44.71% of the company's stock.</p>
<div class="lb-trans"><p>几家大型投资者最近对 HUMA 的持仓进行了调整。Woodline Partners LP 在第四季度将其在 Humacyte 的持股增加了 235.7%。Woodline Partners LP 现在拥有 2,848,802 股公司股票，价值 1,438.6 万美元，此前在上个季度又购买了 2,000,268 股。State Street Corp 在第三季度将其在 Humacyte 的持仓增加了 66.1%。State Street Corp 现在拥有 4,764,155 股公司股票，价值 2,591.7 万美元，此前在上个季度又收购了 1,895,529 股。CenterBook Partners LP 在第四季度购买了 Humacyte 的新头寸，价值约 646.3 万美元。Brevan Howard Capital Management LP 在第四季度将其在 Humacyte 的持仓增加了 2,795.1%。Brevan Howard Capital Management LP 现在拥有 876,340 股公司股票，价值 442.6 万美元，此前在上个季度又购买了 846,070 股。最后，Vanguard Group Inc.在第四季度将其在 Humacyte 的持股增加了 10.8%。Vanguard Group Inc.现在拥有 5,602,684 股公司股票，价值 2,829.4 万美元，此前在上个季度又购买了 543,995 股。机构投资者持有公司 44.71% 的股票。</p>
</div><h2>About Humacyte</h2>
<div class="lb-trans"><h2>关于 Humacyte</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.</p>
<div class="lb-trans"><p>Humacyte, Inc.从事开发和制造现成的、可植入的生物工程人类组织，以治疗多种解剖部位的疾病和状况。该公司利用其专有的科学技术平台，工程化和制造人类无细胞血管（HAV），以便植入患者体内而不引发外来物体反应或导致免疫排斥。</p>
</div><h2>Read More</h2>
<div class="lb-trans"><h2>了解更多</h2>
</div><ul>
<li>Five stocks we like better than Humacyte</li>
<li>3 Best Fintech Stocks for a Portfolio Boost</li>
<li>Top 3 Large Cap Stocks Insiders Bought in Q1: Buy, Sell, or Hold</li>
<li>Health Care Stocks Explained: Why You Might Want to Invest</li>
<li>3 Hot New IPOs Defying the 2025 Market Slump</li>
<li>How to Most Effectively Use the MarketBeat Earnings Screener</li>
<li>3 High-Yield Dividend Stocks Trading at a Discount</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票，胜过 Humacyte</li>
<li>3 只最佳金融科技股票，助力投资组合提升</li>
<li>第一季度内部人士购买的三只大型股：买入、卖出或持有</li>
<li>医疗保健股票解析：为什么你可能想要投资</li>
<li>3 只热销新 IPO，逆势而上，抵御 2025 年市场下滑</li>
<li>如何最有效地使用 MarketBeat 财报筛选器</li>
<li>3 只高收益分红股票，当前交易价格折扣</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9SFVNQQ" alt="" original-src="https://www.marketbeat.com/scripts/InsiderTradesChart.ashx?Prefix=NASDAQ&amp;Symbol=HUMA"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。如对该故事有任何问题或意见，请发送电子邮件至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Humacyte Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Humacyte 吗？</h2>
</div><p>Before you consider Humacyte, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑 Humacyte 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Humacyte wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，建议现在购买，以便在更广泛的市场注意到之前...而 Humacyte 并不在名单上。</p>
</div><p>While Humacyte currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Humacyte 目前在分析师中获得了买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看这五只股票</p>
</div>

Shamik J. Parikh 购买了 7,500 股 Humacyte, Inc.（NASDAQ:HUMA）的股票